Biotie Therapies - Annual report/ annual accounts

Biotie's Annual Report 2009 and Corporate Governance Statement have been published

BIOTIE THERAPIES CORP.     STOCK EXCHANGE ANNOUNCEMENT 15 March 2010 at 1 p.m.
Biotie's Annual Report 2009 and Corporate Governance Statement have been
published

Biotie Therapies Corp.'s Annual Report 2009 and Corporate Governance Statement
have been published as attached to this stock exchange release and on the
company website at www.biotie.com.

The Annual Report including the Financial Statements and the report from the
Board of Directors has been published in Finnish and English.

The printed version of the Annual Report can be ordered at
http://www.biotie.com/In_English/Investors/Financial_Information/Annual_Reports_
2004-2009
or from the company, telephone +358 2 274 8900, e-mail virve.nurmi@biotie.com or
address Tykistökatu 6, 20520 Turku, Finland.

Turku, March 15, 2010

Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:

Virve Nurmi, Investor Relations Manager
tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com<mailto:virve.nurmi@biotie.com>


Distribution:
NASDAQ OMX Helsinki Ltd
Main Media


Biotie Therapies Corp.
Biotie is a drug discovery and development company focused on central nervous
system and inflammatory diseases. It has a broad range of innovative small
molecule and biological drug candidates at different stages of clinical and
pre-clinical development. Biotie's products address diseases with high unmet
medical need and significant market potential, including addiction and psychotic
disorders, rheumatoid arthritis, psoriasis and chronic obstructive pulmonary
disease (COPD). The most advanced product, nalmefene for alcohol dependence, is
currently in phase III clinical development by licensing partner H. Lundbeck
A/S.

The commercial value of the pipeline has been demonstrated through existing
alliances with top-tier global pharmaceutical companies such as Lundbeck, Roche
and Pfizer. Biotie has operations in Turku, Finland and Radebeul, Germany.

Biotie shares are listed on NASDAQ OMX Helsinki Ltd.

For more information, please refer to www.biotie.com


[HUG#1393883]

Attachments:

Corporate Governance Statement.pdf

Annual Report 2009.pdf